Google+ Facebook Twitter Twitter

“Tumour-uninformed” blood test

A team of scientists has evaluated the first “tumour-uninformed” test that detects cancer DNA circulating in the blood of patients following treatment.

Unlike previous tests for circulating tumour DNA (ctDNA) in the blood, this test, called Guardant Reveal, does not require knowledge of the particular mutations that were present in the patient’s tumour.

The team evaluated the tumour-uninformed ctDNA assay to detect residual cancer cells in patients who underwent surgery for colorectal cancer.

Instead of relying on DNA sequencing of individual patients’ tumours, the approach looked for known cancer-specific alterations.

When the researchers analysed ctDNA results from 84 patients and examined how accurately the results correlated with cancer recurrence, they found that this “plasma-only” approach was similar in sensitivity and specificity to tumour-informed approaches.

Image credit | Science Photo Library


Related Articles

Laboratory errors in transfusion: Learning for the laboratory

Anne Lockhart, IBMS representative, and Victoria Tuckley from the Serious Hazards of Transfusion (SHOT) scheme explain their latest annual report.


CRISPR treatment for blood diseases

A collaborative team of researchers has presented preliminary data showing that a CRISPR-based gene-editing therapy for inherited blood disorders is safe and effective.

Brain cancer liquid biopsy

Early detection of brain cancer has moved one step closer, according to new research.

A new screening paradigm

Dr Eric Klein explains why a new blood test that can detect more than 50 types of cancer is set to have a huge clinical impact.